Clinical trials: Atypical Subtrochanteric Fracture
Osteoporosis, Bone Diseases, Metabolic
Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study
Background: Osteoporosis is a condition where the bone becomes more brittle and more likely to break as a person ages. The drugs that people take to treat this condition have prevented many common hip fractures.
- Conditions
- Osteoporosis, Bone Diseases, Metabolic, Hip Fractures
- Trial name
- NCT01360099
- Where
- 2 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Atypical Femur Fracture, Atypical Subtrochanteric Fracture
Atypical Fracture Cohort Study
Osteoporosis is a disease characterized by increased bone fragility and deteriorating bone micro-architecture. The main consequence of osteoporosis is low-trauma fractures, most often of the hip, spine and wrist.
- Conditions
- Atypical Femur Fracture, Atypical Subtrochanteric Fracture, Osteoporosis With AFf
- Trial name
- NCT01747291
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- University Health Network, Toronto
Atypical Femur Fracture
Quebec Registry for Atypical Femur Fractures
Bisphosphonates are recommended as first-line agents to reduce fracture risk in patients with osteoporosis and have in general an excellent safety profile.
- Trial name
- NCT02150850
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- McGill University